Computational study of the binding mode of epidermal growth factor receptor kinase inhibitors

被引:13
|
作者
Chen, Hai-Feng [1 ]
机构
[1] Shanghai Jiao Tong Univ, Coll Life Sci & Biotechnol, Shanghai 200240, Peoples R China
关键词
additional descriptors; docking; epidermal growth factor receptor kinase; support vector machine;
D O I
10.1111/j.1747-0285.2008.00656.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epidermal growth factor receptor kinase is relative to the progression of various types of cancers. In order to design anticancer drug, docking and support vector machines were used to guide CoMFA and CoMSIA for constructing optimal 3D-QSAR model. Additional descriptors, log P and HOMO, combined with several fields of CoMFA and CoMSIA, were introduced to construct models for the inhibitor of epidermal growth factor receptor kinase. The results show that the inclusion of log P and HOMO energy is meaningful for 3D-QSAR model. The validation of these models was testified by some structurally diverse compounds, which were not included in the CoMFA and CoMSIA models. The docking study and molecular dynamic simulation permit us to insight into the binding mode between ligand and EGFR kinase, and provide important information for structure-based drug design. The proposed approach can also be extended to other QSAR investigations.
引用
收藏
页码:434 / 446
页数:13
相关论文
共 50 条
  • [11] Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
    Jimeno, Antonio
    Hidalgo, Manuel
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2006, 1766 (02): : 217 - 229
  • [12] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Depression Reply
    Morgan, Jeffrey A.
    Quek, Richard
    George, Suzanne
    Block, Susan D.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : E51 - E51
  • [13] Pharmacophore analysis of epidermal growth factor receptor tyrosine kinase inhibitors
    Peng, T
    Pei, JF
    Zhou, JJ
    ACTA CHIMICA SINICA, 2003, 61 (03) : 430 - 434
  • [14] Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors
    Rae, JM
    Lippman, ME
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (02) : 99 - 107
  • [15] Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
    Ciardiello, F
    DRUGS, 2000, 60 (Suppl 1) : 25 - 32
  • [16] Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Rukazenkov, Yuri
    Speake, Georgina
    Marshall, Gayle
    Anderton, Judith
    Davies, Barry R.
    Wilkinson, Robert W.
    Hickinson, D. Mark
    Swaisland, Alan
    ANTI-CANCER DRUGS, 2009, 20 (10) : 856 - 866
  • [17] Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Kao, Steven C.
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3233 - 3234
  • [18] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [19] Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    James M. Rae
    Marc E. Lippman
    Breast Cancer Research and Treatment, 2004, 83 : 99 - 107
  • [20] Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
    Adjej, AA
    DRUGS OF THE FUTURE, 2001, 26 (11) : 1087 - 1092